Deborah Quinn-Chen, MD
Obstetrics/Gynecology · Burlingame
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: Mills-Peninsula Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Quinn-Chen’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A60196 · Current
Licensed to practise in California · since 1996 · expires 2028-03-31 · University of Southern California Keck School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$9,439
Medicare paid this office $9,439 for 101 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 32 | $2,831 | $69 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 44 | $2,099 | $48 |
| New patient visit (30+ min) | 13 | $1,247 | $96 |
| Return visit (30+ min) | 11 | $1,132 | $103 |
Who their Medicare patients are
101 Original Medicare patients in 2024. Average age 73 · Women 100% · Health risk score 0.64. At or below the middle of the specialty; the typical obstetrics & gynecology clinician is at 0.88.
Conditions among them: High blood pressure 47% · Diabetes 19% · Cancer 18%.
The office billed $37,705, Medicare allowed $12,975 and paid $9,439; for 131 services of 18 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 101 | 131 | 73 | 0.64 | $37,705 | $9,439 |
| 2023 | 105 | 128 | 75 | 0.86 | $36,954 | $9,675 |
| 2022 | 97 | 143 | 74 | 0.74 | $44,585 | $11,692 |
| 2021 | 116 | 148 | 73 | 0.75 | $37,872 | $11,604 |
| 2020 | 87 | 115 | 73 | 0.74 | $29,710 | $8,262 |
| 2019 | 100 | 128 | 71 | 0.91 | $34,528 | $8,808 |
| 2018 | 92 | 132 | 72 | 0.87 | $29,693 | $8,685 |
| 2017 | 82 | 126 | 72 | 0.94 | $41,735 | $10,590 |
| 2016 | 68 | 100 | 74 | 0.77 | $23,239 | $6,444 |
| 2015 | 57 | 105 | 75 | 0.68 | $26,619 | $7,710 |
| 2014 | 43 | 87 | 73 | 0.72 | $44,013 | $9,553 |
| 2013 | 40 | 66 | 75 | 0.53 | $17,642 | $4,675 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 50 | $2,399 | $48 |
| Short return visit (20+ min) | 26 | $1,947 | $70 |
| Return visit (30+ min) | 17 | $1,762 | $104 |
| New patient visit (30+ min) | 12 | $1,074 | $90 |
2022: 3 services
| Short return visit (20+ min) | 30 | $2,852 | $79 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 50 | $2,360 | $47 |
| Return visit (30+ min) | 15 | $2,115 | $106 |
2021: 4 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 62 | $2,952 | $48 |
| Short return visit (20+ min) | 27 | $2,191 | $68 |
| Return visit (30+ min) | 16 | $1,984 | $124 |
| New patient visit (30+ min) | 14 | $1,402 | $100 |
2020: 3 services
| Short return visit (20+ min) | 27 | $2,080 | $65 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 41 | $1,969 | $48 |
| Return visit (30+ min) | 12 | $1,156 | $89 |
2019: 4 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 42 | $1,964 | $47 |
| Short return visit (20+ min) | 23 | $1,631 | $53 |
| Return visit (30+ min) | 17 | $1,550 | $91 |
| New patient visit (30+ min) | 16 | $1,450 | $91 |
2018: 4 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 51 | $2,291 | $45 |
| Short return visit (20+ min) | 18 | $2,136 | $63 |
| Return visit (30+ min) | 17 | $1,767 | $93 |
| New patient visit (30+ min) | 12 | $1,203 | $100 |
2017: 3 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 47 | $2,152 | $46 |
| Short return visit (20+ min) | 21 | $1,718 | $54 |
| Return visit (30+ min) | 13 | $939 | $72 |
2016: 4 services
| Short return visit (20+ min) | 17 | $1,751 | $55 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 27 | $1,234 | $46 |
| Return visit (30+ min) | 14 | $1,227 | $82 |
| New patient visit (30+ min) | 12 | $1,086 | $91 |
2015: 2 services
| Short return visit (20+ min) | 24 | $3,197 | $63 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 18 | $865 | $48 |
2014: 1 service
| Short return visit (20+ min) | 22 | $2,199 | $61 |
2013: 2 services
| Short return visit (20+ min) | 18 | $1,996 | $57 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 18 | $821 | $46 |
Drugs they prescribed that Part D paid
$17,352
Pharmacies billed $17,352 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
184 generic and 36 brand-name prescriptions · $17,352 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Estradiol | 52 | $4,472 | $86 |
| Estradiol (Twice Weekly) | 42 | $3,175 | $76 |
| Progesterone | 34 | $1,742 | $51 |
| Gabapentin | 18 | $87 | $5 |
Year by year
| 2024 | 220 | 73 | None | 16% | $17,352 |
| 2023 | 157 | 60 | 0% (0) | 23% | $17,552 |
| 2022 | 164 | 47 | None | 30% | $22,130 |
| 2021 | 148 | 53 | 0% (0) | 30% | $19,339 |
| 2020 | 111 | 44 | 0% (0) | 36% | $16,925 |
| 2019 | 112 | 38 | None | 36% | $16,070 |
| 2018 | 135 | 38 | 0% (0) | 40% | $18,622 |
| 2017 | 126 | 32 | None | 40% | $17,727 |
| 2016 | 121 | 34 | 0% (0) | 33% | $12,977 |
| 2015 | 120 | 24 | 0% (0) | 26% | $9,040 |
| 2014 | 79 | 21 | None | 22% | $6,504 |
| 2013 | 92 | 23 | 0% (0) | 50% | $8,602 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Estradiol | 47 | $6,637 | $141 |
| Estradiol (Twice Weekly) | 33 | $2,710 | $82 |
| Progesterone | 25 | $1,377 | $55 |
2022: 5 drugs
| Estring | 11 | $5,567 | $506 |
| Estradiol | 41 | $5,556 | $136 |
| Estradiol (Twice Weekly) | 34 | $2,824 | $83 |
| Progesterone | 15 | $825 | $55 |
| Clobetasol Propionate | 13 | $627 | $48 |
2021: 4 drugs
| Estradiol | 43 | $6,004 | $140 |
| Estring | 12 | $5,749 | $479 |
| Divigel | 21 | $3,267 | $156 |
| Estradiol (Twice Weekly) | 11 | $773 | $70 |
2020: 3 drugs
| Estradiol | 33 | $7,227 | $219 |
| Tranexamic Acid | 11 | $910 | $83 |
| Estradiol (Once Weekly) | 13 | $854 | $66 |
2019: 1 drug
| Estradiol | 69 | $8,538 | $124 |
2018: 4 drugs
| Estradiol | 36 | $4,006 | $111 |
| Premarin | 12 | $3,187 | $266 |
| Yuvafem | 16 | $2,791 | $174 |
| Medroxyprogesterone Acetate | 12 | $79 | $7 |
2017: 3 drugs
| Estrace | 14 | $3,743 | $267 |
| Estradiol | 30 | $3,378 | $113 |
| Medroxyprogesterone Acetate | 17 | $143 | $8 |
2016: 5 drugs
| Estrace | 12 | $3,048 | $254 |
| Vagifem | 11 | $1,882 | $171 |
| Alora | 11 | $982 | $89 |
| Estradiol | 14 | $285 | $20 |
| Medroxyprogesterone Acetate | 28 | $254 | $9 |
2015: 3 drugs
| Estrace | 11 | $2,373 | $216 |
| Estradiol | 39 | $1,685 | $43 |
| Medroxyprogesterone Acetate | 35 | $248 | $7 |
2014: 2 drugs
| Estradiol | 20 | $974 | $49 |
| Medroxyprogesterone Acetate | 17 | $121 | $7 |
2013: 2 drugs
| Estradiol | 18 | $1,000 | $56 |
| Medroxyprogesterone Acetate | 15 | $97 | $6 |
Money from drug and device companies
$103 in 2022
| 2022 | 1 | 1 | None | $103 |
| 2019 | 1 | 1 | None | $31 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Mayne Pharma | None | $103 | 1 payment
|
See the published payment
| Mayne Pharma | Meals · 2022-05-09 | None | $103 |
See earlier years (2019)
2019: $31
| AMAG Pharmaceuticals | Intrarosa | $31 | 1 payment
|
Professional record
- NPI
- 1124110333
- Licence
- CA A60196California A60196: Current · expires 2028-03-31
- Trained
- University of Southern California Keck School of Medicine, 1994
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207V00000X (207V00000X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2006-09-28
- NPI last updated
- 2020-06-22
- NPI record certified
- 2020-06-22
This is when the NPI record was last certified, not a medical board exam.